Aripiprazole (Abilify) is an atypical antipsychotic (AAP) and is the only drug
Originally designed
Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wide and optimal dosage remains unclear
Aripiprazole
The FDA has approved Abilify as an adjunctive treatment for adults with major depressive disorder (MDD) without psychotic symptoms and when
As adjunctive treatment to antidepressant therapy in adults with major depressive disorder, ABILIFY Oral starting dose is 2 mg/day to 5 mg/day with a maximum dose of 15 mg/day
1 out of 10 from a total of 127 reviews for the treatment of Major Depressive Disorder
ABILIFY has been evaluated for safety in 13,543 adult patients who participated in multiple-dose, clinical trials in schizophrenia, bipolar disorder, major depressive disorder, Dementia of the
fatigue
This medicine may also be used in combination with antidepressants to treat major depressive disorder
Antipsychotic drugs like aripiprazole primarily manage psychosis, a mental disorder in which the mind loses touch with reality
Antidepressant non-response is common in major depressive disorder (MDD)
It is sometimes used to treat symptoms of ADHD off-label
major depressive disorder, adjunct tx [2-15 mg PO qd] Start: 2-5 mg PO qd, may incr
ABILIFY MAINTENA ® (aripiprazole) is a prescription medicine given by injection by a healthcare professional for: treatment of schizophrenia in adults
But in 2015, the FDA approved a generic version of Abilify
It affects the entire body and mind, leading to reductions in quality of life and significant costs to the health care sector and society
This includes schizophrenia, bipolar disorder, major depressive disorder, and irritability associated with autism
JOURNAL CLUB
ABILIFY is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)